Thinly traded Kura Oncology (KURA +40.2%) is enjoying a considerable lift from the rally in Syndax Pharmaceuticals (SNDX +53.8%) after the latter announced positive early-stage data on candidate SNDX-5613, a small molecule inhibitor designed to block the interaction between a tumor suppressor protein called menin and another protein called MLL that plays a key role in the development of acute leukemia.
Kura also has a menin-MLL inhibitor in development, KO-539, currently in Phase 1/2 development.
https://seekingalpha.com/news/3565368-syndax-rally-lifts-kura-oncology-up-40
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.